QSAM Biosciences

Biotechnology, Health Care, Life Science
Founded in 2004-01-01
Austin, Texas, United States
http://qsambio.com/
For Profit

About QSAM Biosciences

QSAM Biosciences is a developer of nuclear medicines for the treatment of cancer and related diseases and conditions. Its initial technology is Samarium-153 DOTMP, aka CycloSam, a clinical-stage bone targeting radiopharmaceutical​ developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.

Company Metrics

  • Employees: 1-10
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue:
  • Total Funding: 200000 USD
  • Last Funding: 200000 USD (Debt Financing)
  • Funding Status:

Technology Stack

QSAM Biosciences actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Life Science

Headquarters: Austin, Texas, United States